Clinical trial
An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
NCT05210530 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
- Lead sponsor
- CRISPR Therapeutics AG
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 24, 2022
- Completion date
- January 19, 2023
- Enrollment
- 7 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.